

Special Issue

Adjuvant Therapies for Cancer Treatment

Message from the Guest Editors

To improve cancer survival and prevent the recurrence of the disease and metastasis, we still need to find new compounds and therapeutic strategies, as well as apply drug repurposing and combined therapies. Adjuvant therapy is used after an initial treatment or before as a neoadjuvant. Both applications have advantages (such as reducing the tumor size, preventing tumor cells to spread/metastasis, and eliminating any remaining malignant cells after surgery and disease recurrence) and disadvantages (such as serious side effects). Omics studies and biological approaches have brought a lot of knowledge about alterations and signaling deregulations and profiles related to outcome and drug efficacy. However, the next steps in oncology will be to connect molecular data with clinical practice and offer a potential and specific protocol to the patient for cancer treatment. This Special Issue is dedicated to illustrating the new findings in adjuvant therapy applied for cancer treatment and highlights the gaps and new directions in this field.

Guest Editors

Prof. Dr. Fuyi Wang

CAS Key Laboratory of Analytical Chemistry for Living Biosystems, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China

Dr. Andréia Machado Leopoldino

Department of Clinical Analyses, Toxicology and Food Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, Universidade de São Paulo (USP), Sao Paulo 14040-903, Brazil

Deadline for manuscript submissions

closed (24 February 2025)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/165493

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)